Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Lymphoma, Large-Cell, Anaplastic

ClinicalTrials.gov lists 394 trials for Lymphoma, Large-Cell, Anaplastic or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 58.

MeSH D017728 Neoplasms Neoplasm C04 C15 C20 Listed by Orphanet as a rare disease
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 148 Phase 1/2 Phase 1/2 43 Phase 2 Phase 2 107 Phase 2/3 Phase 2/3 2 Phase 3 Phase 3 30 Phase 4 Phase 4 4 Not applicable Not applicable 29 Observational Observational 27 Phase 1 Phase 1 148 Phase 1/2 Phase 1/2 43 Phase 2 Phase 2 107 Phase 2/3 Phase 2/3 2 Phase 3 Phase 3 30 Phase 4 Phase 4 4 Not applicable Not applicable 29 Observational Observational 27

Trials per phase (log scale)

2 more sections with rows

394 of the 394 trials are tagged with Lymphoma, Large-Cell, Anaplastic itself; the rest are tagged with a narrower condition beneath it.

Get the Lymphoma, Large-Cell, Anaplastic report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Lymphoma, Large-Cell, Anaplastic trials start? (35)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 2 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Unknown)

Top of scale: 27

1990: 1 trials (Not applicable 1) 1992: 2 trials (Phase 2 2) 1993: 1 trials (Phase 2 1) 1994: 2 trials (Phase 1 2) 1996: 5 trials (Observational 2, Phase 1 3) 1997: 12 trials (Not applicable 2, Phase 3 1, Phase 2 1, Phase 1/2 1, Phase 1 7) 1998: 10 trials (Phase 3 1, Phase 2/3 1, Phase 2 1, Phase 1 7) 1999: 23 trials (Not applicable 1, Phase 3 5, Phase 2 5, Phase 1/2 1, Phase 1 11) 2000: 16 trials (Not applicable 1, Phase 3 3, Phase 2 7, Phase 1/2 2, Phase 1 3) 2001: 12 trials (Not applicable 1, Phase 3 2, Phase 2 3, Phase 1/2 1, Phase 1 5) 2002: 12 trials (Not applicable 1, Phase 4 1, Phase 3 1, Phase 2 1, Phase 1 8) 2003: 14 trials (Observational 1, Phase 3 3, Phase 2 5, Phase 1/2 2, Phase 1 3) 2004: 20 trials (Observational 1, Not applicable 3, Phase 2 9, Phase 1 7) 2005: 21 trials (Observational 2, Phase 3 2, Phase 2 12, Phase 1/2 1, Phase 1 4) 2006: 20 trials (Not applicable 2, Phase 3 2, Phase 2 5, Phase 1/2 2, Phase 1 9) 2007: 27 trials (Observational 1, Not applicable 5, Phase 3 2, Phase 2 6, Phase 1/2 3, Phase 1 10) 2008: 22 trials (Observational 3, Not applicable 2, Phase 3 2, Phase 2 2, Phase 1/2 3, Phase 1 10) 2009: 24 trials (Other 1, Observational 3, Not applicable 2, Phase 3 1, Phase 2 6, Phase 1/2 4, Phase 1 7) 2010: 19 trials (Observational 2, Not applicable 1, Phase 3 1, Phase 2 5, Phase 1/2 1, Phase 1 9) 2011: 16 trials (Observational 2, Not applicable 1, Phase 2 5, Phase 1/2 3, Phase 1 5) 2012: 11 trials (Phase 2 5, Phase 1/2 2, Phase 1 4) 2013: 14 trials (Observational 1, Not applicable 1, Phase 3 1, Phase 2 2, Phase 1/2 3, Phase 1 6) 2014: 6 trials (Observational 1, Phase 4 1, Phase 2 1, Phase 1/2 1, Phase 1 2) 2015: 8 trials (Not applicable 1, Phase 4 1, Phase 2 4, Phase 1/2 1, Phase 1 1) 2016: 6 trials (Not applicable 1, Phase 2 5) 2017: 8 trials (Observational 1, Phase 2 3, Phase 1/2 1, Phase 1 3) 2018: 8 trials (Observational 2, Phase 2 3, Phase 1/2 2, Phase 1 1) 2019: 7 trials (Observational 1, Phase 2 3, Phase 1/2 1, Phase 1 2) 2020: 4 trials (Phase 1/2 3, Phase 1 1) 2021: 6 trials (Phase 4 1, Phase 3 1, Phase 2 2, Phase 1 2) 2022: 5 trials (Not applicable 1, Phase 1/2 2, Phase 1 2) 2023: 5 trials (Observational 2, Phase 2/3 1, Phase 1/2 1, Phase 1 1) 2024: 5 trials (Phase 3 1, Phase 1 4) 2025: 6 trials (Phase 3 1, Phase 2 1, Phase 1/2 1, Phase 1 3)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 5
2025 6
2024 5
2023 5
2022 5
2021 6
2020 4
2019 7
2018 8
2017 8

Showing 10 of 35 earlier years.

Start your 14-day trial Email me all 35 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 7 trials starting in 2026 and about 6 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 15 trials still running at the 2026-10-09 snapshot; registered median of 48 months across 311 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Lymphoma, Large-Cell, Anaplastic trials in? (10)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 148
Phase 1/2 43
Phase 2 107
Phase 2/3 2
Phase 3 30
Phase 4 4
Not applicable 29
Observational 27
Expanded access 3
Unknown 1

How many Lymphoma, Large-Cell, Anaplastic trials are recruiting? (10)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 4
Recruiting 18
Active, not recruiting 13
Completed 254
Suspended 3

Showing 5 of 10 statuses.

Start your 14-day trial Email me all 10 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Lymphoma, Large-Cell, Anaplastic trials? (6)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 58
Seagen Inc. 11
Eastern Cooperative Oncology Group 7
National Institutes of Health Clinical Center (CC) 7
Children's Oncology Group 6

Showing 5 of 6 sponsors.

Start your 14-day trial Email me all 6 sponsors as a PDF

Which drugs are being tested for Lymphoma, Large-Cell, Anaplastic? (3)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Cytoxan 63
RITUXIMAB 26
Prednisone 26

Interventions as named in the registry (12)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
SQ Fludarabine 39
Peripheral blood stem cell transplantation 37
Doxorubicine 31
Etoposid 31
Total Body Irradiation 28

Showing 5 of 12 interventions.

Start your 14-day trial Email me all 12 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Lymphoma, Large-Cell, Anaplastic trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Febrile neutropenia 357 36
Neutrophil count decreased 181 24
Platelet count decreased 154 20
Pneumonia 122 23
unplanned hospitalisation (emergency case) 112 1

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Lymphoma, Large-Cell, Anaplastic? (56)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-up. Blood cancer journal 2025 Yes
Transient responses and significant toxicities of anti-CD30 CAR T cells for CD30+ lymphomas: results of a phase 1 trial. Blood advances 2024 Yes
Stratified Treatment in Pediatric Anaplastic Large Cell Lymphoma: Result of a Prospective Open-Label Multiple-Institution Study. Cancer research and treatment 2024 Yes
Crizotinib in Combination With Chemotherapy for Pediatric Patients With ALK+ Anaplastic Large-Cell Lymphoma: The Results of Children's Oncology Group Trial ANHL12P1. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2023 Yes
Efficacy and safety of crizotinib in ALK-positive systemic anaplastic large-cell lymphoma in children, adolescents, and adult patients: results of the French AcSé-crizotinib trial. European journal of cancer (Oxford, England : 1990) 2023 Yes

Showing 5 of 56 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Prevalence (3)

Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.

Prevalence
Orphanet disease Type Class Geography Jurisdiction Mapping relation
Anaplastic large cell lymphoma Point prevalence 1-9 / 100 000 Europe Not stated Exact
Anaplastic large cell lymphoma Point prevalence 1-9 / 100 000 Europe Not stated Exact
Anaplastic large cell lymphoma Point prevalence 1-9 / 100 000 Europe Not stated Unspecified

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Anaplastic large cell lymphoma 98841 Exact Orphanet Rare Disease Ontology (ORDO)
Anaplastic large cell lymphoma 98841 Exact Orphadata Science knowledge files, Product 1

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: sub-conditions in mesh.

Browse all condition evidence pages